Medicare Part D 2010 Data Spotlight: Coverage of Top Brand-Name and Specialty Drugs
This Part D Data Spotlight documents the wide variations across the private stand-alone drug plans with respect to coverage of drugs, what enrollees pay for those drugs, and restrictions and limitations placed on their use. These variations have potentially significant implications for beneficiaries’ access to medications and out-of-pocket costs.
The spotlight is one in a series analyzing key aspects of the Medicare Part D drug plans that will be available to beneficiaries in 2010. The analysis was conducted jointed by Jack Hoadley and Laura Summer of Georgetown University, Elizabeth Hargrave of NORC at the University of Chicago, and Juliette Cubanski and Tricia Neuman of the Kaiser Family Foundation.
Data Spotlight (.pdf)
also of interest
- To Switch or Be Switched: Examining Changes in Drug Plan Enrollment among Medicare Part D Low-Income Subsidy Enrollees
- A Primer on Medicare: Key Facts About the Medicare Program and the People it Covers
- Medicare at a Glance
- Raising Medicare Premiums for Higher-Income Beneficiaries: Assessing the Implications